| アブストラクト | AIM: To examine healthcare resource utilization in type 2 diabetes (T2D) patients after initiation of sodium-glucose co-transporter-2 inhibitors (SGLT-2is) versus dipeptidyl peptidase-4 inhibitors (DPP-4is) or other glucose-lowering drugs (oGLDs). MATERIALS AND METHODS: A cost-utilization analysis was performed using a nationwide hospital-based administrative claims database (Medical Data Vision) during 2014-2018 in Japan, where universal healthcare coverage is maintained under a single-payer system. Data on T2D patients initiated on either SGLT-2is or oGLDs during the study period (228 514 patients) were extracted and subjected to a 1:1 propensity score-matching analysis (7626 patient pairs for DPP-4is and 28 484 for oGLDs). Direct healthcare resource utilizations and inpatient and outpatient costs were compared. RESULTS: After matching, baseline characteristics were well balanced, including healthcare costs within 3 and 12 months before the index date (standardized difference <5% for all variables), with a mean age of 61.6-64.1 years. While diabetes medication costs were higher in patients initiated with SGLT-2is than in those initiated with DPP-4is or oGLDs, further breakdown of individual cost components showed that SGLT-2is were associated with a lower hospitalization frequency and a shorter total hospital stay (by 213.0 or 204.6 days/100 patient-years compared with DPP-4is or oGLDs, respectively; P < .001). Accordingly, overall mean cumulative cost per patient at the 2.5-year postindex date was lower in patients with SGLT-2is than in those with DPP-4is or oGLDs by $2545 (1384.6-3759.7) and $2330 (1793.1-2882.9), respectively (P < .001). CONCLUSIONS: Our results show the benefits in healthcare resource utilization associated with SGLT-2i use in Japanese T2D patients. |
|---|
| ジャーナル名 | Diabetes, obesity & metabolism |
|---|
| 投稿日 | 2021/4/10 |
|---|
| 投稿者 | Kohsaka, Shun; Takeda, Masayoshi; Kidani, Yoko; Yajima, Toshitaka |
|---|
| 組織名 | Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.;Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka,;Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33835640/ |
|---|
